Allon’s clinical development strategy is direct: Build a strong safety foundation in large conventional Phase I studies and then identify multiple opportunities to define human efficacy Phase II studies. Allon’s current studies are designed to show efficacy and provide valuable data on the best end points and patients for subsequent studies.

Allon has two products in human clinical trials: AL-108 and AL-208. The Company currently has three separate Phase II human efficacy trials in clinical development evaluating the potential of AL 108 as treatments for Alzheimer’s disease and schizophrenia cognition, and a third evaluating AL 208 as a treatment for the Mild Cognitive Impairment associated with Coronary Artery Bypass Graft surgery (MCI-CABG).

Allon’s technology platforms

Allon's neuroprotective compounds are derived from two technology platforms: Activity-Dependent Neuroprotective Protein (ADNP) and Activity-Dependent Neurotrophic Factor (ADNF). ADNP and ADNF are two classes of proteins that treat or protect neurons against degenerative diseases and injuries.

Both platforms originated from studies on vasoactive intestinal peptide (VIP). VIP is an important neuroprotective peptide. In early studies, VIP was shown to be a broad neuroprotectant, causing the neuroprotective proteins ADNP and ADNF to be secreted from glial cells or brain support cells.